Late Prolia Injection: Catch-Up Dates, Fracture Evidence and Next Steps

Start with the injection record

For a missed Prolia injection, U.S. labeling directs administration as soon as the patient is available, followed by injections every six months from the actual catch-up date. Administration is by a healthcare provider. Prolia and Xgeva both contain denosumab; their products and schedules differ. [1]

Before calling, find the administration record rather than relying on an appointment reminder: a booked visit does not prove an injection happened. Tell the clinic whether you want to continue treatment or are considering stopping. Those conversations require different plans.

For planning visits before a dose is overdue, use the routine Prolia appointment guide.

Your catch-up date worksheet

Use this record during the clinic call, then complete it after the visit:

Illustration: a February 15 injection leads to an August 15 due date. If the catch-up injection occurs September 3, the next date is March 3. Six calendar months is not necessarily 26 weeks or 182 days. Reset reminders after administration, not merely after booking. [1]

Keep both the original due date and actual injection date: replacing one with the other hides the length of the delay. Ask the clinic to reconcile conflicting records before calculating the next appointment.

How to read the delay and discontinuation studies

A UK observational cohort included 2,594 people aged 45 or older. Researchers measured lateness from the recommended injection date: within four weeks, four to 16 weeks, or more than 16 weeks afterward. These are not intervals measured from the last injection. [5]

For delays exceeding 16 weeks, the vertebral-fracture hazard ratio was 3.91 compared with on-time dosing (95% confidence interval, 1.62–9.45). The composite-fracture estimate was less conclusive: 1.44 (0.96–2.17). Treatment timing was not randomized, so these associations neither establish a harmless grace period nor predict one person's risk. [5]

Discontinuation evidence addresses a different question. A post hoc analysis of FREEDOM and its extension included 1,001 denosumab discontinuers who had received at least two doses and remained under observation at least seven months after their last dose. Vertebral-fracture rates rose from 1.2 during treatment to 7.1 after stopping, per 100 participant-years—not a 7.1% two-year risk. Among those with an off-treatment vertebral fracture, 60.7% had multiple fractures; that percentage does not describe all discontinuers. [6]

Prepare a focused clinic call

Have the worksheet ready and ask:

• Is treatment continuing, or does the prescriber need to discuss a transition?
• What is the earliest appropriate appointment, and who will confirm it?
• Does a new diagnosis, medicine or symptom change the assessment before treatment?
• If dental care caused the delay, can the dentist and prescriber coordinate?
• Who will update the next due date and help resolve insurance or access barriers?

For postmenopausal osteoporosis, Endocrine Society guidance advises against delaying or stopping denosumab without subsequent therapy because of rebound bone turnover, bone-density loss and fracture risk. It does not select a universal bridge drug or schedule. Raise uncertainty about continuing rather than allowing an overdue appointment to become an unplanned stop. [2]

Dental work alone does not establish a reason to skip an injection. The ADA resource, updated in April 2023, finds insufficient evidence for routine osteoporosis-drug holidays or waiting periods to prevent medication-related jaw osteonecrosis. CTX testing is not a validated predictor of that complication. Coordinate individual dental planning with both clinicians. [4]

Kidney disease needs a separate safety plan

FDA warns of severe hypocalcemia in advanced chronic kidney disease, especially dialysis and CKD-mineral and bone disorder. A late appointment does not remove the need for expert assessment, clinician-directed supplementation and monitoring. Do not substitute an online supplement plan for that assessment. [3]

For advanced CKD, labeling specifies calcium monitoring weekly during the first month after administration and monthly thereafter. This is not an all-patient missed-dose testing schedule. [1]

Report new severe back pain or a possible fracture promptly. [7] Muscle spasms, tingling, confusion or seizures can signal serious hypocalcemia; severe symptoms require urgent medical attention rather than waiting for the rescheduled visit. [3]